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The renin–angiotensin system (RAS) 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 2. Clinical trials of renin–angiotensin system targeting treatments in calcific aortic valve disease (CAVD).  
aortic stenosisa 
RIASa Ramipril vs. placebo 100 1 year Moderate or 
severe asymp- 
tomatic AS 
LVM, systolic velocity, progression of 
CAVD by cardiac magnetic 
resonance 
proBNP 
Reduction in LVM, pre- 
served systolic pres- 
sure, non-significant 
reduction in pro- 
gression of CAVD 
(29) 
ROCK-ASa Candesartan vs. 
placebo 
51 5 months Severe AS Mortality, LV mass and function, 6-min 
walking test, Nt-proBNP 
(24) 
Status of the study acompleted, bunknown, and congoing. 
AS:  aortic stenosis; NYHA: New York Heart Association; BP: blood pressure; SAC: systemic aortic compliance; NT-proBNP: N-terminal pro-brain natriuretic peptide; Zva: valvuloarterial impedance; LVM: left ventricular  
mass; BAV: bicuspid aortic valve; MRI: magnetic resonance imaging; TEE: transthoracic echocardiography. 
ACCESS: Acute Haemodynamic Effects of Treatment With Angiotensin Converting Enzyme (ACE)-Inhibitors in Patients With Symptomatic Aortic Stenosis; ALFA: A Randomized Trial of Angiotensin Receptor blocker, 
Fimasartan, in Aortic Stenosis; BAV: Beta Blockers and Angiotensin Receptor Blockers in Bicuspid Aortic Valve Disease Aortopathy; RIAS: A prospective, double-blind: randomized controlled trial of the angiotensin- 
converting enzyme inhibitor Ramipril In Aortic Stenosis; ROCK-AS: The Potential of Candesartan to Retard the Progression of Aortic Stenosis; SCOPEAS: Safety and efficacy of angiotensin-converting enzyme inhibitors   

















SCOPE-ASa Enalapril vs. placebo 56 1 month (3 month Symptomatic Development of hypertension, Borg Improvement in NYHA (26) 
follow-up for severe dyspnea index, 6-min walk distance, class, Borg index 
selected patients) off-target drug effects, NYHA-class and 6-min walk dis-  
     changes, echocardiographic tance. 
parameters Benefit greatest in 
patients with regur-  
      gitant valve lesions 
Effects of angiotensin converting Various ACEIs, cross- 20 Not reported Asymptomatic AS Hemodynamic and functional variables Reduction in afterload, (27) 
enzyme inhibitors in hypertensive over design (withdrawal compensated by 
patients with aortic valve stenosis: a study) increase in trans-  
drug withdrawal studya valvular pressure 
gradient. 
Hemodynamic varia-  
      bles improved in 
most hypertensive 
patients. 
Short-term hemodynamic effect of Trandolapril vs. 44 8 weeks Severe AS Acute hemodynamic effects of ACEI, Reduction in left ven- (28) 
angiotensin-converting enzyme placebo change in systemic BP, SAC, Zva, tricular end systolic 
inhibition in patients with severe NT-proBNP, exercise capacity volume and NT-  
ACCESSb Captopril or trandolap- 64 8 weeks Severe AS Hemodynamic and functional NCT00252317 
ril vs placebo parameters 
ALFAb Fimasartan vs. placebo 100 1 year Moderate to Change of VmaxO2 in cardiopulmonary NCT01589380 
severe AS exercise test, various hemodynamic 
parameters, LVM, hospitalization, 
mortality 
BAV studyc Telmisartan vs. pla- 85 5 years BAV, no CAVD at Change from baseline in ascending NCT01202721 
cebo. Parallel arm baseline aorta size, as evaluated by MRI; rate 
tests atenolol vs. of change in ascending aorta size 
placebo. evaluated by (TEE) 
The effect of losartan in bicuspid aortic Losartan (open label, 25 1 year BAV, no CAVD at Inflammatory blood markers NCT01390181 
valve patients.b single group) baseline 
Renin, prorenin and (pro)renin receptor 
–
Bradykinin and bradykinin receptors 
a a
Endothelin and endothelin receptors 
–- - -
- 
Apelin – APJ system 
–
–Natriuretic peptides 
" # $ 
" # $ 
Table 3.  Expression of vasoactive peptides in calcified aortic valves (vs normal)  and their localization in calcified valves/normal 
valves. 
Expression Localization is stenotic valves 
N/A 
N/A 
N/A N/A N/A N/A 
N/A N/A N/A 
N/A 
ETB $ 




Corin $ N/A N/A N/A N/A N/A (78) 
Furin # N/A N/A N/A N/A N/A (78) 
ANP $ N/A N/A N/A N/A N/A (78,94) 
BNP $ N/A N/A N/A N/A N/A (78,94) 
CNP # # # $       N/A     $      (78,94) GC-
A   # N/A      N/A             N/A      N/A      N/A      (78,94) GC-B     
# N/A      N/A   N/A        N/A       N/A         (78,94) NPR-C        $ 
N/A         N/A       N/A        N/A       N/A        (78,94) NEP " " " N/A " N/A (50) 
B1R " " " $ " N/A (50) 
B2R " $ $ $ " N/A (50) 
Upregulated ( ), downregulated ( ) or unchanged ( ) gene/protein expression in stenotic aortic valves compared to uncalcified valves. N/A, no studies 
performed to date. 
Angiotensin converting enzyme (ACE) and type 2 (ACE2); angiotensin type 1  (AT1) and  type  2 (AT2)  receptor; APJ: apelin receptor; atrial (ANP)  and B-type  
natriuretic peptide (BNP); bradykinin B1 (B1R) and B2 (B2R) receptor; CNP (C-type natriuretic peptide); ECE-1: endothelin converting enzyme 1; ET-1: endo-      thelin-
1; endothelin receptor A (ETA) and B (ETB); GC: guanylyl cyclase; NEP: neutral  endopeptidase;  natriuretic  peptide  receptor  C  (NPR-C);  (P)RR:  renin  receptor. 
Figure 1. Vasoactive peptides in calcific aortic valve disease. A schematic illustration summarizing peptides involved in comprehen- 
sive shift in the balance of valvular RAS components towards activated ACE/AngII/AT 1-receptor-mediated fibrosis, proliferation and 
inflammation in AS. Black arrows show reported upregulated (  ), downregulated (  ) or unchanged (  ) gene expression in stenotic 
aortic valves. 
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